Novogen up on preclinical data

NVGN was up $2.43 (42%) to $8.18 on Wednesday after announcing that its phenoxodiol inhibits sphingosine kinase, an enzyme NVGN said promotes solid tumors via angiogenesis and prevents tumor cells fro...